Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Praxis Precision Medicines (PRAX) Equity Average (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Equity Average data on record, last reported at $610.8 million in Q4 2025.

  • For Q4 2025, Equity Average rose 47.52% year-over-year to $610.8 million; the TTM value through Dec 2025 reached $610.8 million, up 47.52%, while the annual FY2025 figure was $661.8 million, 156.95% up from the prior year.
  • Equity Average reached $610.8 million in Q4 2025 per PRAX's latest filing, up from $373.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $610.8 million in Q4 2025 and bottomed at $70.3 million in Q1 2023.
  • Average Equity Average over 4 years is $256.3 million, with a median of $164.9 million recorded in 2022.
  • Peak YoY movement for Equity Average: tumbled 48.44% in 2023, then surged 429.4% in 2024.
  • A 4-year view of Equity Average shows it stood at $90.6 million in 2022, then fell by 13.71% to $78.2 million in 2023, then soared by 429.4% to $414.1 million in 2024, then surged by 47.52% to $610.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $610.8 million in Q4 2025, $373.9 million in Q3 2025, and $421.7 million in Q2 2025.